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E. faecalis, sensltlve to ampicillin and glycopeptides
(vancomycin and teicoplanin), but expressing high-
level gentamicin resistance. The patient was treated
with a combination of intravenous ampicillin and
teicoplanin (for which in vitro synergy was demon-
strated) for 2 weeks followed by oral amoxycillin plus
intramuscular teicoplanin for 4 weeks. She awaits
assessment for the second stage of her surgery.
These patients demonstrate several of the etiologic
factors which predispose to prosthetic joint infection:
urologic trauma (case 1), rheumatoid arthritis and
postoperative trauma (case 2). Both cases highlight the
need to collect multiple specimens for culture in order
to make the diagnosis and guide antimicrobial therapy.
Enterococci may cause up to 10% of prosthetic joint
infections and are associated with urologic or gastro-
intestinal procedures [1]. Enterococci are inherently
resistant to the usual orthopedic perioperative anti-
biotic prophylaxis regimens. Until recently enterococci
were predictably sensitive in vitro to combinations of
ampicillin or a glycopeptide antibiotic (vancomycin,
teicoplanin) with an aminoglycoside. However, the
presence of high-level gentamicin resistance abolishes
the potential for synergistic use of aminoglycosides [2].
More recently, both acquired ampicillin resistance and
resistance to glycopeptide drugs have emerged in
enterococci, leading to hospital outbreaks of multiply-
resistant organisms [3]. There is currently a need
for novel therapeutic approaches in order to achieve
cidal antimicrobial activity against enterococci. As
nosocomial infections due to these organisms, notably
multiply-resistant E. faecium, increase, we can expect to
encounter more enterococcal joint infections. The
prevention of such infections requires a reconsideration
of antibiotics for prophylaxis and in cement, as high-
lighted in recent correspondence [4], together with
aggressive management of predisposing perioperative
factors.
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Treatment of disseminated Mycobacterium simiae
infection in AIDS
Clin Microbiol lrifect 1997; 3: 265-267
Mycobacterium simiae is a rare cause of human infection.
It is usually considered to be a commensal in the
sputum ofpatients with underlying pulmonary diseases
[1]. Only a small percentage of immunocompetent
patients have had proven clinical disease [2]. In recent
years, M. simiae has been reported as a cause of dis-
seminated infection in five patients with AIDS [3-6].
Two patients were co-infected with the M. avium
(MAl) complex [4,5]. In three cases, M. simiae was the
only microorganism isolated (from blood culture,
sputum and bone marrow), clearly demonstrating
the pathogenic role of M. simiae [3,6]. The choice of
optimal therapy is unclear, and the outcome was poor
in the five cases previously reported [3-6]. We report
a case of disseminated M. simiae infection in a patient
with AIDS, who was succe5.sfully treated with a
combination regimen that comprised clarithromycin,
sparfloxacin and cycloserine.
A 52-year-old caucasian heterosexual man was
found to be HIV positive in 1989. He had a history of
sexual contacts with prostitutes in Burkina Faso. He
had been treated with zidovudine since October 1990
and was asymptomatic. In September 1994, after travel
to Burkina Faso, he presented with fever, diarrhea and
weight loss of 6 kg. His CD4 cell count was 45/mm3 .
CT scans of the thorax and abdomen showed three
right pulmonary parenchymal nodular opacities and
retroperitoneal lymphadenopathy (1 x 2 cm). All other
investigations were negative and no infective agent
was detected in initial tests. He was treated empirically,
for suspected disseminated MAl infection, with
clarithromycin (2000 mg/day), rifabutin (600 mg/day)
and ethambutol (1200 mg/day). Staining of several
sputum specimens revealed acid-fast bacilli. The patient
responded to this therapy within 2 weeks. Culture from
blood, sputum induction and bronchoalveolar lavage
yielded M. simiae (identified by the National Myco-
bacterium Reference Laboratory). Rifabutin was
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discontinued because of arthralgia and ofloxacin was
added. In spite of this treatment, the patient's condition
deteriorated, in January 1995, with intermittent fever
and weight loss. In March 1995, repeat CT scan
revealed mediastinal, intra-abdominal and retroperi-
toneallymphadenopathies with central cavitation (2 x 3
cm). His blood culture on this occasion was negative
for M. simiae. The initial isolates of M. simiae were
found to be sensitive in vitro to rifabutin and cyclo-
serine, but resistant to clofazimine, ciprofloxacin,
amikacin, ofloxacin and ethambutol. The MlC of
clarithromycin was 16 Ilg/mL. Therapy was changed
to clarithromycin (2000 mg/day), cycloserine (500
mg/day) and sparfloxacin (250 mg/day), with sub-
sequent clinical and radiologic improvement. Cyclo-
serine was discontinued in November 1995 because of
dizziness. The patient was still alive in August 1996.
This patient was born in France but lived tran-
siently in Burkina Faso. Among the five cases described
in the literature, two patients lived in Israel [3], one
patient was born in Puerto Rico and lived in New
York City [5]; and two patients were born and lived in
Africa (Congo [4] and Burundi [6]). The relatively high
prevalence of M. simiae infection in the Israeli AIDS
patients seems to be related to the high prevalence of
this species in Israel [3]. A similar association has been
reported between M. kansasii infection and AIDS
patients from Northern Texas, an area in which this
species is hyperendemic. Our patient and two cases
described in the literature lived in Africa. M. simiae
should be added to the growing list ofnon-tuberculous
mycobacteria that infect AIDS patients, especially those
who live in areas where the prevalence of this organism
is high [6-8].
The diversity of mycobacterial species infecting
patients with AIDS makes full identification imperative
as a guide to appropriate therapy. Guidelines for
chemotherapy of M. simiae infections suggest that the
drug regimens proposed for treatment of MAl infect-
ions should be used and that antibiotic susceptibilities
should be determined [8]. M. simiae is resistant in
vitro to conventional antituberculous drugs [3,9], but
appears to be susceptible to ethionamide, cycloserine,
clofazimine and amikacin [10]. Unfortunately, in vivo
data are limited, although combination therapy with
rifampin, clofazimine and amikacin demonstrated
efficacy against M. simiae in a murine model [11].
Recently, the activities in vitro and in vivo of newer
antimycobacterial agents such as macrolides and quino-
lones have been studied [10] and suggest a potential role
for clarithromycin and ofloxacin in the treatment of
M. simiae infection [10]. Our patient was successfully
treated with a combination regimen including clarithro-
mycin, sparfloxacin and cycloserine, despite multiple
drug resistance in vitro. He responded also to the first
combination regimen that included clarithromycin,
rifabutin and ethambutol. These encouraging results
suggest an important role for these agents in the
treatment of human M. simiae infections. More studies,
however, are needed to determine the activities of
other agents, in order to optimize therapy for this
multidrug-resistant mycobacterial species.
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Lyme disease presenting as prolonged pyrexia of unknown
origin
Clin Microbiol Infect 1997; 3: 267-268
Borreliosis includes within its definition both relapsing
fever and Lyme disease. Relapsing fever has been
recognized in our province since at least the 1930s [1]
and is thought to be caused by Borrelia hermsii, which
is transmitted by the soft tick Ornithodoros hermsii.
Anecdotes of relapsing fever are reported on an almost
yearly basis in British Columbia and Alberta, although
few of these cases are published [2], and one of the
largest recognized outbreaks of tick-borne relapsing
fever in North America was recognized in the Browne
Mountain area of Washington state, in close proximity
to the British Columbia-Washington border [3]. In
addition, Lyme disease has been recognized among
British Columbians, although travel to other endemic
areas is a feature in the history of most patients.
Whereas the clinical manifestations of Lyme disease are
now well detailed for both children and adults [4,5], a
relapsing fever pattern or prolonged fever of unknown
origin have not been published in the pediatric medical
literature. We here describe an illness consisting of
prolonged fever of unknown origin which developed
in a child who acquired an endemic Borrelia burgdoiferi
infection in British Columbia.
A 13-month-old-female from central British
Columbia developed a right forearm rash 2 weeks after
an expedition to a lake in central British Columbia in
late June. The parents recalled an 'insect bite' at the site
of the dermatopathy, although a specific insect could
not be defined. The rash was described as having a pale
center and a red expanding circular edge. Coincident
with the disappearance of the rash after 3-4 weeks,
a fever developed and was measured maximally at
approximately 40°C orally. The child received oral
amoxycillin during the time when the fever persisted
but appeared to have a moderate anaphylactoid reaction
consisting of rash and listlessness. Although an anti-
biotic allergy was considered, the child had received
oral amoxycillin on one occasion previously without
side effects. The patient subsequently received oral co-
trimoxazole and the febrile illness resolved over 2
weeks. On a weekly basis thereafter, however, and
for the 6 subsequent months, the fever recurred,
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lasting for 1-3 days and reaching 38-39°C orally.
The febrile episodes were commonly accompanied by
nausea and transient diarrhea. During this interval, the
patient received several antibiotic courses, including
cotrimoxazole and cefaclor for presumed urinary tract
and middle ear infections. Antibiotic use, however, did
not seem to affect the subsequent reappearance of the
febrile illness. Although the forearm rash had com-
pletely disappeared without local residua, both legs and
arms developed areas of eczematoid rash.
Laboratory data during the weekly illnesses were
generally not helpful in providing a diagnosis, although
two immunofluorescence antibody (IFA) titers to B.
burgdoiferi were both recorded as 11256, at 2 and 3
months after the onset ofillness. The family history was
considerably complicated by the diagnosis of an in-
herited mitochondrial disorder in the father (including
cardiomyopathy) and two siblings. Furthermore, the
mother had recurrent urinary tract infection and the
father required a right nephrectomy because of a
complicated ureteral obstruction. There was no history
of travel outside British Columbia.
The child was admitted to our children's hospital 6
months after the onset for investigation of the fever
recurrences and an apparent failure to thrive in the
context of the familial history of metabolic disease. A
change in weight from 50th percentile (birth) to 5th
percentile was observed. The child was afebrile at the
time of admission and the last febrile episode had
ceased 2 days before. Physical examination could not
determine a focus for infection. There was no evidence
of joint, central nervous system or cardiac disease.
Laboratory investigations revealed: white blood cell
(WBC) 10.0 x 109 /L (60% lymphocytes), hemoglobin
112 giL, and platelets 300 x 109 /L. Serum electrolytes,
creatinine, lactate, liver and muscle enzyme profiles
and amino acids were within the normal range. Both
electrocardiogram and echocardiogram were normal. A
repeat of the B. burgdoiferi serology once again revealed
an IFA titer of 11256. An IFA titer to B. hermsii was less
than 1/128. Western blot serology using B. burgdoiferi
antigen demonstrated immune recognition of seven
polypeptides in addition to the flagellar (41 kDa),
OspA and OspB antigens.
Fever was not recorded during 5 days in hospital
but returned 7 days later and again recurred on a
weekly basis. Oral erythromycin was administered
by the seventh month and continued for 10 days.
The child was afebrile during the antibiotic course
and has remained so after cessation of the same,
apart from a single episode of fever associated with
a urinary tract infection. The eczematoid rash dis-
appeared after the erythromycin treatment and has not
recurred.
